The development of an in vivo model for the study of CML would be of significant importance in studying its biological behavior and developing novel therapeutic strategies. We examined the ability of human leukemic cells derived from patients in either chronic (CP), accelerated (AP) or blast phase (BP) CML to grow and disseminate in CB17-SCID mice by subcutaneous (s.c.) inoculation without conditioning treatment or administration of cytokines. Additionally, samples derived from patients with CP-CML were injected s.c. into CB17-SCID mice treated with anti-Asialo GM1 (an anti-NK cell antibody) and NOD-SCID mice (absent NK cell activity) to study the potential role of NK cell-mediated anti-leukemic activity in preventing the propagation of CP-CML cells. We observed a significant differential growth pattern of CML cells in the mice such that BP-CML grew rapidly as s.c. tumors and disseminated, while AP-CML or CP-CML cells grew temporarily as small nodules that spontaneously regressed and did not disseminate. This differential growth pattern suggests possible important biological differences. Furthermore, no significant difference in s.c. growth or dissemination of CP-CML samples derived from newly diagnosed patients in untreated CB17-SCID mice and CB-17 SCID mice treated with Anti-Asialo GM1 and NOD-SCID mice occurred, suggesting that factors other than NK cell anti-leukemic activity may be important. Keywords: microenvironment; blast phase; accelerated phase; chronic phase; subcutaneous Chronic myelogenous leukemia (CML) is an acquired malignant disorder of the hematopoietic stem cell and is characterized by the proliferation of clonal myeloid cells and their progenitors.
The product of this rearrangement is a bcr-abl hybrid gene, which encodes a p210 protein product with tyrosine kinase activity and is thought to have leukemogenic properties. 4 CML typically begins as an initial chronic phase (CP) which lasts approximately 4-6 years with eventual progression to blastic transformation commonly heralded by the acquisition of additional chromosomal abnormalities by Ph + stem cells including duplication of the Ph chromosome, isochromy 17q and trisomy of chromosomes 8, 19 or 21. 5, 6 The relationship of these non-random chromosomal changes to the progression of this disease is not well understood. The majority of patient-derived CML cells have limited proliferative capacity in vivo and available in vitro assays are only capable of detecting progenitors with limited proliferative and replating potential. 7, 8 An in vivo model of CML would potentially allow for the development of novel therapeutic strategies in the treatment of this disease as well as possibly lead to the elucidation of the molecular events involved in the evolution of the CP to blastic phase (BP).
Several recent studies have shown the growth of some human leukemia cells in the severe combined immunodeficiency (SCID) mouse model in a manner analogous to their clinical characteristics in patients. [9] [10] [11] [12] This has allowed the propagation of human leukemic cells that in prior studies failed to grow in vitro or in nude mice. Although several reports demonstrate the feasibility of consistently growing human acute myeloid and lymphoid leukemias in SCID mice the growth of CML cells in this model have mostly been limited to cell lines or samples derived from patients in the BP of the disease. [13] [14] [15] [16] Only one group has been able to demonstrate even limited growth of CP-CML cells in SCID mice; this growth was limited to the bone marrow and Ph + cells were identified in only a small minority of the animals studied. 17 Recently, we developed a SCID mouse model that permits the s.c. growth of primary human acute leukemia cells. 9 Furthermore, the s.c. growth in this model is associated with dissemination of the leukemia reflecting a pattern of growth similar to the usual clinical presentation. To determine whether and to what degree different phases of CML would grow or disseminate within the SCID mouse model, we subcutaneously inoculated SCID mice with samples of cells derived from patients with CP, AP or BP-CML. Additionally, several samples derived from patients with CP-CML were injected subcutaneously into SCID mice treated with anti-Asialo GM1 (an anti-NK cell antibody) and NOD-SCID mice (absent NK cell activity) to study the potential role of NK cell-mediated anti-leukemic activity in preventing the propagation of CP-CML in SCID mice.
In this report we demonstrate a differential growth pattern of patient-derived CP and AP vs BP CML in a SCID mouse by s.c. inoculation and present the characteristic and biologic behavior of the human chronic myelogenous leukemias in this model.
Materials and methods

Leukemic samples
Samples were obtained, with informed consent, during routine diagnostic blood studies or bone marrow (BM) aspirates from patients with newly diagnosed or previously diagnosed and treated chronic myeloid leukemias at Memorial Sloan-Kettering Cancer Center (MSKCC). Seventeen CPCMLs, two AP-CMLs and eight BP-CMLs were studied. Blast-enriched mononuclear cells were isolated by FicollHypaque density gradient separation and washed in RPMI 1640 medium. After separation, most of the leukemic cells were freshly inoculated into SCID mice. In some patients, leukemic cells were cryopreserved in liquid nitrogen before their injection into the animal.
SCID mice
All SCID (CB17-SCID/SCID and NOD-SCID) mice were purchased from Taconic Farms (Germantown, NY, USA) and maintained in micro-isolator cages under sterile conditions with a specific pathogen-free environment without the use of any antibiotics. Female SCID mice between 6 and 8 weeks of age were used. This work was approved by the MSKCC Animal Review Board and all animals were sacrificed in accordance with MSKCC Animal Research regulations. The number of SCID mice inoculated and the cell dose per mouse were dependent on the number of leukemic cells available from patient samples. The animals did not receive any conditioning treatment before inoculation. Thirty microliters of anti-Asialo GM1 (Wako Pure Chemical Industries, Osaka, Japan) were administered to CB-17 SCID mice intraperitoneally on days −1 (prior to the s.c. inoculation), 4 and 8, and every 5-7 days thereafter for the duration of the study. 18 Treatment of Mouse NK cells have the immunophenotype asialo GM1 + , NK-2.1
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− , and Lyt-2 − , and are thought to play an important role in endogenous in vivo resistance against transplanted cells and this resistance has been overcome in SCID mice by the administration of anti-Asialo GM1. 19 Leukemic cell growth was assessed by weekly measurements of the dimensions of subcutaneous nodules. Tumor size was calculated by taking the square of the mean radii and multiplying by . Animals inoculated with BC-CML leukemic cells were sacrificed by cervical dislocation when the dimensions of subcutaneous nodules were at least 1.5 cm 2 or more than 3 months after inoculation. Animals inoculated with AP-CML and CP-CML leukemic samples were sacrificed in the same manner when tumor nodule size reached maximal size or more than 3 months after inoculation. The gross anatomy was evaluated and samples from peripheral blood, sternum, femur, spleen, liver, lung-heart complex, kidney, brain and tumor nodules were subsequently removed for analysis by flow cytometry (FACS), fluorescent in situ hybridization (FISH), polymerase chain reaction (PCR) for detection of bcr-abl transcripts, and histologic analysis.
Analysis of tissue from xenografted animals
Histopathology: Tissue sections from killed SCID mice were fixed in 10% neutral-buffered formalin, dehydrated, embedded in paraffin, sectioned and stained according to standard histologic techniques.
Immunophenotyping: Cell suspensions derived from tissues of killed animals and primary CML cells were washed in phosphate-buffered saline (PBS) and stained with directly labeled fluorescein isothiocyanate (FITC)-conjugated and phycoerythrin (PE)-conjugated monoclonal antibodies for 30 min at 4°C. The cells were then washed twice and analyzed by FACS (Becton Dickinson, Mountain View, CA, USA). The following antibodies were used for characterization of lineage surface markers: CD13, CD14, CD15, CD33, CD34, CD7, DR (Becton Dickinson). Additionally, FACS analyses of samples of blood, BM, spleen and liver from animals were performed by using two-color immunofluorescence staining and pairwise combinations of a selected panel of antibodies (CD3-PE, CD19-PE, CD33-PE and CD45-FITC) against human antigens and an antibody mCD45-FITC (Boehringer Mannheim, Indianapolis, IN, USA) against a murine antigen to discern the origins of the cells.
FISH:
FISH was performed as previously described. 9 In brief, single-cell suspensions from tumor nodules or organs were washed and fixed in a mixture of methanol and acetic acid (3:1 v/v). The cells were put on to slides and air-dried. Subsequently, the slides were washed at room temperature (RT) in successive jars containing 0.1 n HCl solution containing 0.5% Triton, PBS, 1% formaldehyde, PBS × 2, 2 × SSC and denatured at 72°C in 70% formamide/2 × SSC. Thereafter, the slides were dehydrated by 2 min of exposure to graded ethanol solutions at 4°C. Denatured probes (10 mg/ml biotin-labeled; Oncor, Gaithersburg, MD, USA) in a hybridization solution (Hybrisol VI; Oncor) were deposited on slides and covered with a coverslip. The slides were sealed with rubber cement, and then the hybridization took place in a moistened chamber at 37°C for 12-18 h. After hybridization, the slides were washed in 65% formamide/2 × SSC at 43°C and then in 2 × SSC at 37°C and rinsed in 1 × SSC RT. Biotinylated probes for human X chromosome were detected by applying 20 ml detection reagent containing avidin/FITC (Oncor), the plastic coverslip was added, and the slide was incubated in a humidified chamber at 37°C for 30 min. The slides were then washed in 1 × SSC at RT three times and propidium iodide (2 mg/ml; Sigma, St Louis, MO, USA) was applied for counterstain. A Zeiss fluorescence microscope (Axioskop; Carl Zeiss, Pelham, NY, USA) was used for visualization and at least 200 cells were scored.
PCR:
To detect bcr-abl transcripts, RNA was prepared from blood, BM, liver, spleen, and tumor cells. To prepare the cDNA, between 2 and 5 g of total RNA was added to a reverse transcriptase reaction.
A nested PCR technique was used, as previously described. PCR product was run on an ethidium bromidestained 2% agarose gel and visualized under UV light. Using this approach, we were able to detect a single control-positive (K562) cell in 10 6 normal cells. In order to minimize contamination, the recommendations of Kwok and Higushi were adopted. 19 Cytogenetic analysis: Samples of cells recovered from leukemic nodules and from patient-derived tissues were examined for their karyotype by standard techniques. A minimum of 20 metaphases was examined for each sample. Table 1 summarizes the clinical characteristics of the 27 patients with CML evaluated in this study. The ages of patients ranged from 11 to 63 years. Patients were classified according to CML phase: CP-CML (17 cases), AP-CML (two cases), BP-CML (eight cases). One and three of the patients with AP-CML and CP-CML, respectively, were newly diagnosed and untreated.
Results
Characteristics of patients
Engraftment and growth pattern of BP-CML in SCID mice
Leukemic cells from seven of eight patients with BP-CML (87.5%) were able to grow as s.c. nodules in SCID mice ( Table 1 ). The mean time for leukemia nodule growth to reach 0.8 cm 2 (diameter = 1.0 cm) and 2.0 cm 2 (diameter = 1.6 cm) of surface area in mice bearing these seven BP-CML was 9.4 (Ϯ 4.9) and 15.6 (Ϯ 5.8) weeks after inoculation, respectively (Figure 1a ). Leukemic cells from five of seven (BC6 has not yet been sacrificed) patient-derived samples that grew as subcutaneous nodules disseminated to and infiltrated extensively the BM, peripheral blood (PB), spleens and livers of the animals as assessed by FISH, FACS and PCR analysis ( Table 2) . Leukemia dissemination was also found in lung, kidney, brain and spleen of the animals on pathologic examination. One patient-derived specimen (BC7) grew as a small s.c. tumor and demonstrated minimal systemic dissemination, although there was gross liver and splenic enlargement, only rare leukemic cell detection was demonstrated in BM and liver by FACS analysis. Leukemic cells from patient BC8 failed to either engraft as an s.c. nodule or disseminate to distant organs in SCID mice recipients.
Engraftment and growth pattern of BC-CML in secondary SCID mice passages
After adoptive growth of leukemic samples derived from patients BC1, BC2, BC3 and BC4 in SCID mice, specimens were obtained from leukemic s.c. tumors and passaged in secondary SCID mice by s.c. inoculation using the same amount of cells and same methodology as utilized during the first passages. All four specimens generated s.c. tumor growth in the secondary SCID mice. The blast cells derived from two patients (BC1 and BC3) displayed a similar growth and dissemination pattern when compared with their leukemia growth in the first SCID passages ( Figure 2 and Table 2 ). However, leukemic cells derived from patients BC2 and BC4 displayed more rapid leukemic sub- cutaneous tumor growth in the secondary SCID mice in contrast to the first passage (Figure 2 ).
Engraftment and growth pattern of AP-CML in SCID mice
Leukemic cells derived from two AP-CML patients were inoculated into SCID mice. The leukemic cells from two of two patients with AP-CML grew transiently as subcutaneous nodules without subsequent dissemination to distant organs (Table 1) . Leukemic cells derived from patient AC1 gradually generated an s.c. tumor with a maximal size of 0.5 cm 2 approximately 5-6 weeks after inoculation, thereafter, the tumor size slowly regressed (Figure 1b) . Additionally, samples derived from patient AC2 grew as s.c. tumors in both CB17 and NOD-SCID mice. The time for the leukemia nodule to reach 0.8 cm 2 in CB17 and NOD mice was 14.5 weeks and 7 weeks, respectively, however, the tumor sizes in these animals did not exceed 1 cm 2 . Seventeen and 12 weeks after inoculation, the tumors began to spontaneously regress in the CB17 and NOD-SCID mice, respectively (Figure 3) . In none of these animals were spleen or liver enlargement or other clinical signs that indicated leukemia development evident. Furthermore, there was no evidence of leukemic cell infiltration of distant organs detectable by FISH, FACS, histopathological or RT-PCR analysis of the tissues performed at 5-10 weeks post inoculation.
Engraftment and growth pattern of CP-CML in SCID mice
Samples derived from 17 CP-CML patients were included in this study. Leukemic cells from seven of 17 patients (CP1-7) grew transiently as subcutaneous nodules without resultant dissemination to distant organs as determined by FISH, FACS and histopathological analysis (Tables 1 and  2 ). No leukemic nodule reached a size of 0.8 cm 2 in the mice bearing these seven CP-CML samples (Figure 1c) , with the exception of leukemic cells derived from patient CP5 and inoculated into NOD-SCID mice (CP5n) which generated a maximal tumor size of 0.8 cm 2 5 weeks after inoculation (Figure 3) . Three of these seven patient-derived samples were obtained from newly diagnosed patients (CP5, CP6, CP7) who had not yet received any treatment. The s.c. nodules resultant from the seven inoculated specimens which generated tumors all spontaneously regressed starting at approximately 5 weeks. Subcutaneous tissue analysis by FACS, FISH and histopathology at the site of tumor cell injection revealed minimal or no residual tumor cells present at the time of animal sacrifice. RT-PCR analysis for the bcr-abl fusion gene transcription product in different organs in the mice inoculated with higher numbers of leukemic cells derived from newly diagnosed and untreated patients (CP5, CP6, CP7) indicated that minimal dissemination to distant organs of leukemic cells occurred in these animals ( Table 2) .
Furthermore, analysis for the bcr-abl transcript by RT-PCR analysis with primer B 2 A 2 revealed positive findings in the s.c. tumor and liver in CB17 SCID mice (CP6a) sacrificed at 5 weeks, whereas animals sacrificed at 7 weeks (CP6b) displayed positive findings in bone marrow and liver with no positive findings in the tumor. None of the tissues from these animals revealed positive RT-PCR findings when the control primer B 3 A 2 was utilized for leukemic cell detection.
With the exception of the PCR results, there was no significant difference in s.c. tumor growth characteristics between samples obtained from either newly diagnosed or previously treated patients with CP-CML. Ten CP-CML 
ND = not done; NG = no growth; S = sacrifice; D = died; TU = tumor; BM = bone marrow; PB = peripheral blood; SP = spleen; LI = liver; KI = kidney; BR = brain; n = nod scid mouse.
(CP8-17) samples, all derived from patients previously treated, failed to grow as subcutaneous nodules or to disseminate to distant organs. To address the possibility of leukemia rejection by mouse NK cells, we compared the leukemic cell engraftment and growth in CB17 SCID mice treated with Anti-Asialo GM1 or NOD-SCID mice with leukemic cell growth in CB17 SCID mice without any treatment. There were no discernible differences in subcutaneous tumor growth in CB17 SCID mice treated with Anti-Asialo GM1 (CP5a), NOD-SCID mice (CP5n and CP7n) and untreated CB17 SCID mice (CP5 and CP7) ( Figure 3) .
As mentioned, sample CP7 induced subcutaneous tumor growth in both CB17 SCID (CP7) mice and NOD-SCID (CP7n) mice and there was no demonstrable difference in nodule growth characteristics or dissemination patterns. RT-PCR analysis for bcr-abl breakpoint B 3 A 2 revealed positive findings in the spleen and tumor of CP7 mice, while CP7n mice demonstrated positive findings in the tumor only; none of the animals demonstrated positive findings when the control primer B 2 A 2 was utilized for leukemic cell detection.
Cytogenetic and phenotypic analysis of recovered leukemic cells from mouse tissues
Cytogenetic analysis of leukemic cells recovered from leukemic nodules growing in SCID mice inoculated with BP-CML demonstrated significant evolutionary changes including chromosomal duplications and additional complex translocations (Table 3) . Phenotypically, the leukemic cells recovered from leukemic nodules induced by specimens BC1 and BC2 demonstrated an evolution to a less mature phenotype than was predominant in the original samples, however, leukemic cells recovered from leukemic nodules induced by specimen BC3 demonstrated a more mature phenotype than was predominant in the original sample ( Table 4 ). The leukemic cells recovered from leukemic nodules in animals inoculated with sample BC4 displayed the same phenotype as the original sample.
Discussion
In this study we have demonstrated for the first time that BP-CML cells, like primary acute leukemias, 9 can engraft after s.c. inoculation in SCID mice without conditioning treatment or the administration of growth-promoting cytokines. Moreover, the xenografted tumor cells subsequently disseminate to distant organs in a pattern similar to that seen in the patients from whom they were derived.
BP-CML cells demonstrated remarkable cytogenetic and phenotypic changes from preimplantation to the time of tumor harvest. Additionally, second passage of BP-CML cells (BC2, BC4) derived from the subcutaneous tumors of first passage SCID mice demonstrated a more rapid growth pattern and reached a greater maximal tumor size than was found in the first passage mice. This may have represented the selective growth of a leukemic population of cells not detected in the initial cytogenetic analysis, or the original leukemic cells may have undergone an evolution to more complex chromosomal abnormalities expressed as the demonstrated cytogenetic and phenotypic abnormalities. The latter explanation would be consistent with previously described evidence for a multi-step pathogenesis in the progression of CP-CML to BP-CML. 5, 20 We observed distinct differences in the growth characteristics of leukemic cells derived from patients in BP-CML as compared to CP-CML or AP-CML. Seven of eight BP-CML samples grew in a manner analogous to human AML Weeks post-inoculation Surface area (cm2) CP5 CP5a CP5n CP7 CP7n Figure 3 Growth curves of CP-CML samples derived from patients CP5 and CP7 and injected into CB17 SCID mice (CP5 (n = 4), CP7 (n = 2)), CB17 SCID mice treated with Anti-Asialo GM1 (CP5a (n = 4)), and NOD-SCID mice (CP5n (n = 3), CP7n (n = 2)). No significant difference either in rate of tumor growth or maximal tumor size (mean surface area) reached was detected between these groups of mice. and ALL in the SCID mice. 9 However, CP-CML and AP-CML only grew either transiently as s.c. tumors which spontaneously regressed, or not at all. We did not observe a difference between the ability of samples derived from either newly diagnosed and untreated patients vs patients already receiving treatment. Although subcutaneous tumor cells generated from CP-CML samples initially demonstrated bcr-abl transcripts by RT-PCR analysis, animals sacrificed at a later date demonstrated disappearance of the positive RT-PCR signal initially found in these tumor cells, consistent with the morphologic regression of these tumors. The differential growth pattern described here is similar to that previously demonstrated in SCID mice utilizing the renal capsule as the site of injection. 13 Although it has been demonstrated in several studies that CML cell lines and patient-derived BP-CML cells, utilizing varying routes of administration, can grow and disseminate in SCID mice, s.c. growth of patient derived BP-CML has not yet been reported. [13] [14] [15] [16] Additionally, no reliable and consistent in vivo model for the growth of CP-CML has been developed. Sirard et al 17 have recently reported growth of normal and leukemic cells in the bone marrow of sublethally irradiated SCID mice after intravenous infusion of patient-derived CP-CML samples. However, in only a small proportion of marrows growing human hematopoietic cells was the presence of the bcr-abl transcript identified. Additionally, in this study the CP-CML cells did not disseminate in a manner analogous to the pattern seen in humans.
It has been suggested that there may be a relationship between the inoculated cell dose of patient-derived CML samples and the subsequent growth of both leukemic cells and normal hematopoietic cells in SCID mice. 17 In this study we utilized a median cell dose of 2 × 10 7 and may have achieved better engraftment with higher cell doses. However, even when CP-CML tumors grew as subcutaneous nodules there was a subsequent spontaneous and complete tumor regression.
It has been postulated that intact NK cell function may contribute to the lack of growth of CP-CML cells in SCID mice. 17 We did not observe any growth difference in CB17-SCID mice treated with an anti-NK cell antibody when compared to untreated CB17 SCID mice. Additionally, we were unable to propagate CP-CML cells in NOD-SCID (NK-deficient) mice. Our results suggest that factors other than NK cell activity are responsible for the lack of growth and propagation of CP-CML in SCID mice.
One possible explanation for the observed differential growth is that, although propagation of BP-CML cells occur by autocrine mechanisms, continued growth of CP-CML or AP-CML may require stromal components or microenvironmental factors depleted or absent in the Ficoll-Hypaque density fraction. It has been reported that abnormalities in the CML marrow microenvironment related to the presence of malignant stromal macrophages may contribute to the selective expansion of leukemic progenitors and suppression of normal hematopoiesis in CML. 21 Moreover, successful engraftment of SCID mice with primitive CP-CML progenitor cells has been reported after the implantation of human fetal bone fragments, presumably containing all the requisite stromal components. 22 Additional manipulations of the SCID mouse model to more closely approximate the human CML marrow microenvironment may be required to achieve durable transplantion of CP-CML cells.
In conclusion, the subcutaneously inoculated SCID mouse leukemia model appears to accurately reflect the intrinsic biologic behavior of BP-CML. The subcutaneous engraftment and resultant dissemination of BP-CML in this model may provide an important tool for the study of CML biology and the development of novel therapeutic strategies such as immunotherapeutic manipulations or pharmocologic agents such as angiogenesis inhibitors without necessitating the sacrifice of the animals to observe an effect. Further refinements of this model will be necessary for the establishment of a reliable in vivo model for the study of CP-CML.
